ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Atrasentan

Also written as “Drug: Atrasentan”, “atrasentan” and “0.25 mg Atrasentan QD”.

Its studies are mostly in Glomerulonephritis, IGA · Prostatic Neoplasms · Renal Insufficiency, Chronic · Kidney Diseases · Diabetic Nephropathies, led by 3 companies.

Drug pageAtrasentan: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 10, 200215 company-led studies, 4 open or runningNext primary completion: Apr 14, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbottits history only50 open or runningphase 3since May 10, 2002May 10, 2002none ahead
AbbVieits history only50 open or runningphase 3since May 17, 2013Jun 11, 2009none ahead
Novartis54 open or runningphase 3since Sep 12, 2020Sep 12, 2020Apr 14, 2028phase 3 · NCT04573478

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 12, 2020First study: phase 3 study in Glomerulonephritis, IGAFirst studyNCT04573478 · 404 enrolled · United States, Argentina, Australia and more
  2. Sep 28, 2020Phase 2 study in Glomerulonephritis, IGANCT04573920 · 103 enrolled · United States, Australia, Italy and more
  3. Apr 18, 2023Phase 2 study in Glomerulonephritis, IGANCT05834738 · 54 enrolled · United States, Australia, Brazil and more
  4. Mar 23, 2026Phase 3 study in Glomerulonephritis, IGANCT07498335 · 28 planned · United States, China, Colombia and more
  5. Sep 23, 2026Phase 3 study in Glomerulonephritis, IGANCT07850752 · 340 planned

Ahead

  1. Apr 14, 2028Primary completion: phase 3 study in Glomerulonephritis, IGANCT04573478
  2. Sep 17, 2028Primary completion: phase 3 study in Glomerulonephritis, IGANCT07850752
  3. Sep 15, 2031Primary completion: phase 3 study in Glomerulonephritis, IGANCT07498335

TargetBeta

EDNRA →read by rule
“Endothelin receptor ET-A antagonist”ChEMBL 37, by rule

Other programs on EDNRA

ProgramCompanyFurthest phaseStudies
BosentanruleJohnson & Johnsonphase 437
sparsentanruletravere-therapeutics-incphase 49
zibotentanAstraZenecaphase 323
aprocitentanruleIdorsia Pharmaceuticalsphase 314

Studies

All 5 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07850752Glomerulonephritis, IGA3Not yet recruitingSep 17, 2028340
NCT07498335Glomerulonephritis, IGA · United States, China, Colombia and more3RecruitingSep 15, 203128
NCT05834738Glomerulonephritis, IGA · United States, Australia, Brazil and more2CompletedJun 30, 202554
NCT04573920Glomerulonephritis, IGA · United States, Australia, Italy and more2Active, not recruitingJul 2, 2024103
NCT04573478Glomerulonephritis, IGA · United States, Argentina, Australia and more3Active, not recruitingApr 14, 2028404

How it is read

Names in the registry

  • “Atrasentan”, 12 entries
  • “Drug: Atrasentan”, 1 entry
  • “atrasentan”, 1 entry
  • “0.25 mg Atrasentan QD”, 1 entry
  • “0.75 mg Atrasentan QD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.